Your browser doesn't support javascript.
loading
The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL).
Chase, Dana M; Shukla, Soham; Courcy, Joanna de; Ellis, Hilary; Piercy, James; Taylor-Whiteley, Teresa; Golembesky, Amanda; Wethington, Stephanie L.
Afiliação
  • Chase DM; Gynecologic Oncology Division, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7383, USA.
  • Shukla S; Value Evidence & Outcomes, GSK, Collegeville, PA, USA.
  • Courcy J; Adelphi Real World, Macclesfield, UK.
  • Ellis H; Adelphi Real World, Macclesfield, UK.
  • Piercy J; Adelphi Real World, Macclesfield, UK.
  • Taylor-Whiteley T; Adelphi Real World, Macclesfield, UK.
  • Golembesky A; Value Evidence & Outcomes - Oncology, GSK, Research Triangle, NC, USA.
  • Wethington SL; Department of Gynecology & Obstetrics, Johns Hopkins Medicine, Baltimore, MD, USA.
Future Oncol ; 20(2): 83-94, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37701998
What is the article about? The VOCAL study looked at maintenance approach preferences of patients with advanced epithelial ovarian cancer. Maintenance approach refers to the methods used after a patient has completed their initial chemotherapy to prevent disease progression for as long as possible. US patients completed an online survey, ranking five different maintenance approaches: No medication (active surveillance); Once-daily oral medication (e.g. pills); Twice-daily oral medication; Medication by intravenous infusion every 3 weeks; Medication by intravenous infusion every 3 weeks and oral twice-daily. Patients were asked to assume the same time to disease progression for all five approaches and the same side effects for the four approaches involving medications (2­5). Each patient then indicated how much time to disease progression they were willing to trade off to remain on their preferred approach before switching to an alternative. What were the results? Overall, 152 patients completed the survey (median age: 53 years, 68% White). Most patients preferred a medication approach (56%, n = 85) to active surveillance (44%, n = 67). Of the 85 patients who preferred medication, 66% (n = 56) reported this was to feel proactive in preventing their cancer returning. Once-daily oral medication was the most acceptable alternative to the patients' preferred maintenance approach, given they were willing to trade the least 'disease-free' time (2.3 months) before accepting a switch. What do the results mean? Individual patient preferences vary, and healthcare professionals should work with patients to determine which approach is most appropriate for them.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article